Targeting deubiquitinases in hepatocellular carcinoma: a preclinical assessment of the therapeutic potential in combinatory treatments with tyrosine kinase inhibitors and immune checkpoint inhibition. Ghent University
Advanced hepatocellular carcinoma (HCC), the fate of a majority of HCC patients, is a lethal disease. Systemic therapy using tyrosine kinase inhibitors (TKI) or, since November 2020, the combination of a TKI and an immune checkpoint inhibitor (ICI) only provides a short survival benefit for only a subset of patients and exhibits substantial adverse effects. New treatment options using combination therapies are an urgent unmet clinical need. ...